Amvuttra
Payments companies reported to CMS as associated with Amvuttra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Amvuttra, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Amvuttra
These are the largest totals companies reported as associated with Amvuttra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sabahat Bokhari | Allentown, PA | Cardiovascular Disease | $205,414.25 |
| Olakunle Akinboboye | Laurelton, NY | Internal Medicine | $202,353.87 |
| Robert Gottlieb | Dallas, TX | Advanced Heart Failure and Transplant Cardiology | $193,396.26 |
| Naveen Bellam | Orlando, FL | Advanced Heart Failure and Transplant Cardiology | $165,667.29 |
| Abdul Latif Bikak | Marietta, GA | Advanced Heart Failure and Transplant Cardiology | $160,004.38 |
| Brendan Carry | Danville, PA | Advanced Heart Failure and Transplant Cardiology | $143,803.89 |
| Richard Wright | Santa Monica, CA | Advanced Heart Failure and Transplant Cardiology | $142,240.16 |
| Zubair Shah | Kansas City, KS | Advanced Heart Failure and Transplant Cardiology | $132,565.52 |
| Saurabh Malhotra | Buffalo, NY | Cardiovascular Disease | $112,403.98 |
| Christopher Bell | Tupelo, MS | Acute Care (Nurse Practitioner) | $107,389.37 |
Prescribed Amvuttra?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.